암 치료의 역동적인 상황에서 정밀의료의 등장은 치료 패러다임을 일변시키고 개별 종양의 독특한 패턴을 이용한 맞춤형 접근법을 제공합니다. 최근 생명 공학 및 제약 회사의 다양한 이해 관계자의 호기심이 종양 발생 및 진행에 관여하는 주요 분자 촉진요인의 동정에 의해 강조 된 원사이즈 핏 올 모델에서 맞춤화의 치료 전략에 각광을 받게 되어 있습니다. 그 중 CD70 단백질은 유망한 치료 표적으로 부상하여 암 치료 및 기타 치료 영역에서 헤아릴 수 없는 가능성을 가지고 있습니다.
치료 대상으로서의 CD70 연구는 암 환자에게 더 효과적이고, 개별화되고, 맞춤화된 치료 옵션의 파노라마를 확대하고 있습니다. 처음에는 CD70 단백질이 T 세포와 B 세포의 활성화에 관여했습니다. 그러나 전임상시험에서 얻은 증거는 CD70 단백질이 포스파티딜 이노시톨-3 키나아제(PI3K)와 MAP 키나아제 신호 전달 경로의 활성화를 일으킨다는 것을 보여줍니다. 이 신호전달경로의 활성화는 더 많은 수의 전사인자의 활성화를 가져오고, 그에 따라 세포의 증식과 생존에 관여하는 유전자의 발현을 일으켜 암질환의 원인이 됩니다.
전임상시험에 의한 조사 증거 제공은 세계 여러 이해관계자들의 신뢰와 탐구심을 높이는 데 도움이 됩니다. 따라서 수많은 제약 회사와 생명 공학 회사들이 CD70 요법의 개발을 계획하고 임상시험을 시작했습니다. CD70 단백질 치료 시장을 촉진하는 중요한 원동력 중 하나는 새로운 연구를 수행하기위한 공동 연구 증가입니다. 많은 기업들이 연구기관이나 병원과 손을 잡고 CD70 요법 시장을 전진시키고 있습니다. 예를 들어, Chongqing Precision Biotech는 잉여 CD70 전임상 및 임상 연구를 수행하기 위해 중국의 The First Affiliated Hospital of Nanchang University, Zhejiang University, Shanxi Bethune Hospital과 같은 연구 기관 및 병원과 제휴하고 있습니다.
현재, 쿠사투주맙(ARGX-110)은 백혈병 치료제로서 임상 2상 단계에 도달한 가장 진보된 CD70 후보입니다. 항-CD70 항체뿐만 아니라, CAR-T 세포 요법, CAR-NK 요법, CD70 단백질을 표적으로 하는 4특이적 항체 등, 많은 다른 치료 접근법도 CD70 치료의 영역이 해마다 진화하고 있음을 나타냅니다 있습니다. 더욱이, CD70 단백질의 연구가 더욱 진행됨에 따라, 이 영역은 큰 전망과 유익한 미래를 나타냅니다.
이 보고서는 세계 CD70 표적 치료 시장을 조사했으며, 시장 개요와 함께 약물 동향, 임상시험 동향, 지역별 동향 및 시장 진출기업경쟁 구도 등을 제공합니다.
Global CD70 Targeting Therapies Market Opportunity & Clinical Trials Insight 2024 Report Highlights:
In the dynamic landscape of cancer therapeutics, the emergence of precision medicine has transformed treatment paradigms, offering tailored approaches that take advantage of the unique patterns of individual tumors. Recently, the curiosity of various stakeholders from the biotech and pharma companies have turned the limelight from a one size fits all model to a tailored therapeutic strategy that has been underscored by the identification of key molecular drivers implicated in tumorigenesis and progression. Among these, CD70 protein has emerged as a promising therapeutic target, clenching immense potential in the realm of cancer therapy and other treatments.
The research of CD70 as a therapeutic target clenches the panorama of more effective, personalized and customized therapy choices for cancer patients. Initially, the CD70 protein was involved in T cell and B cell activation. However, augmenting evidences from preclinical studies signifies that CD70 protein causes activation of the phosphatidylinositol-3 kinase (PI3K) together with MAP kinase signaling pathways. This activation of signaling pathways further results in activation of numerous transcription factors and thereby the expression of genes involved in cell growth along with survival and causing cancer diseases.
Bestowing research evidences from preclinical studies aid to build confidence and inquisitiveness among various stakeholders across the globe. Therefore, numerous pharma and biotech companies planned to develop CD70 therapy and initiated clinical trials. One of the significant prime movers that aid to advance CD70 protein therapy market is the rise in research collaborations to conduct novel studies. Many firms are joining hands with research institute and hospitals to headway CD70 therapy market. For instance, Chongqing Precision Biotech has partnership with institutes and hospitals, including The First Affiliated Hospital of Nanchang University, Zhejiang University or Shanxi Bethune Hospital etc., in China to conduct surplus CD70 preclinical and clinical studies.
Concurrently, in the pharmaceutical sector, CD70 targeted therapeutic intervention characterize a promising revolution area. Over the preceding decennium, the sphere of global CD70 therapy market has witnessed the development of several novel, innovative as well as advanced contenders targeting CD70. For instance, candidates like SGN-CD70, bi-4SCAR GD2/ CD70 T cells, CD70 CAR-T cells, CB dualCAR- NK19/70, CTX130, CTX131, ALLO-316 and others have been developed by in the preceding years for the treatment of cancer ailments. As research and advancement expands, it is anticipated that numerous other innovative CD70 therapy will be perceived in future.
Moreover, in order to further augment the therapeutic window in conjugation with boost efficacy, pharma companies have initiated the combinational study of CD70 therapy with other therapies. Currently, a handful of combinations of CD70 therapy are being invested with immunotherapies like CAR-T therapy combination or amalgamation of CAR-T with monoclonal antibody, targeted therapies, chemotherapy, epigenetic modulators, oncolytic viruses and others. The combinational study for CD70 therapy represents a novel as well as compelling frontier in the commercial CD70 therapy landscape.
Solitary of the key characteristics which aid to amplify the sphere of CD70 targeted therapy is fostering investments and collaborations. These partnerships and investments among academic institutions, smaller biotech firms, and larger pharmaceutical companies also aid to speed up the discovery and commercialization of CD70 therapy. For instance, in February 2024, ProfoundBio has raised an investment of US$ 112 Million in Series B financing round in order to advance in its preclinical programs, including PRO1160, a CD70 targeted antibody drug conjugate.
All these examples demonstrate that the realm of CD70 therapy is burgeoning at an incredible gait. At present, US dominates the CD70 therapy segment in terms of research and development. However, China is additionally up surging and expanding the CD70 therapy arena by developing innovative CD70 candidates coupled with initiating many clinical trials. The evolutions from one size fits all model to a tailored therapeutic strategy suggests that developing CD70 therapy clenches immense potential.
Currently, Cusatuzumab (ARGX-110) is the most advanced CD70 candidates that have reached phase II clinical stage for leukemia treatment. In addition to anti-CD70 antibodies, multitudinous other therapeutic approach like CAR-T cell therapy, CAR-NK therapy or tetraspecific antibodies targeting CD70 protein represents that the domain of CD70 therapy is evolving year by year. Moreover, as research further increases for CD70 protein, the domain represents a huge prospect and a fruitful future.